AstraZeneca's Lynparza Supplemental New Drug Application Granted Priority Review by FDA
30 Noviembre 2021 - 1:49AM
Noticias Dow Jones
By Anthony O. Goriainoff
AstraZeneca PLC said Tuesday that its Lynparza drug's
supplemental new drug application has been accepted and granted
Priority Review by the U.S. Food and Drug Administration.
Lynparza is used for the treatment of patients with early breast
cancer who have already been treated with chemotherapy either
before or after surgery, the London-listed company said.
The Anglo-Swedish pharmaceutical company said the application
was based on results from the OlympiA phase 3 trial which showed
Lynparza demonstrated a statistically significant improvement in
invasive disease-free survival.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
November 30, 2021 02:34 ET (07:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De May 2023 a May 2024